Fruchtman Steven M 4
4 · Onconova Therapeutics, Inc. · Filed Feb 8, 2023
Insider Transaction Report
Form 4
Fruchtman Steven M
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2023-02-07+21,320→ 47,454 total - Tax Payment
Common Stock
2023-02-07$1.36/sh−6,977$9,489→ 40,477 total - Exercise/Conversion
Restricted Stock Units
2023-02-07−21,320→ 42,640 total→ Common Stock (21,320 underlying)
Footnotes (2)
- [F1]Restricted stock units convert into common stock on a one-for-one basis.
- [F2]On February 7, 2022 the reporting person was granted 63,960 restricted stock units which vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34% on the third anniversary.